These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15025680)

  • 1. Use of an artificial neural network to predict Graves' disease outcome within 2 years of drug withdrawal.
    Orunesu E; Bagnasco M; Salmaso C; Altrinetti V; Bernasconi D; Del Monte P; Pesce G; Marugo M; Mela GS
    Eur J Clin Invest; 2004 Mar; 34(3):210-7. PubMed ID: 15025680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prospective study on the relationship between treatment duration of antithyroid drug and remission rate of Graves' disease].
    Liu C; Duan Y; Wu X
    Zhonghua Yi Xue Za Zhi; 2000 Nov; 80(11):835-7. PubMed ID: 11218878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remission of Graves' hyperthyroidism treated with methimazole.
    Bolaños F; González-Ortiz M; Durón H; Sánchez C
    Rev Invest Clin; 2002; 54(4):307-10. PubMed ID: 12415954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcome of Graves' disease in Thai children.
    Somnuke PH; Pusuwan P; Likitmaskul S; Santiprabhob J; Sawathiparnich P
    J Med Assoc Thai; 2007 Sep; 90(9):1815-20. PubMed ID: 17957924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graves' disease in children and adolescents: response to long-term treatment.
    Barrio R; López-Capapé M; Martinez-Badás I; Carrillo A; Moreno JC; Alonso M
    Acta Paediatr; 2005 Nov; 94(11):1583-9. PubMed ID: 16303698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
    Benker G; Reinwein D; Kahaly G; Tegler L; Alexander WD; Fassbinder J; Hirche H
    Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of smoking on the course of Graves' disease after withdrawal of antithyroid drugs.
    Quadbeck B; Roggenbuck U; Janssen OE; Hahn S; Mann K; Hoermann R;
    Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):406-11. PubMed ID: 17039420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent remission of Graves` disease or evolution from Graves' disease to Hashimoto's thyroiditis in childhood - a report of 6 cases and clinical implications.
    Smyczńyska J; Cyniak-Magierska A; Stasiak M; Karbownik-Lewińska M; Lewiński A
    Neuro Endocrinol Lett; 2014; 35(5):335-41. PubMed ID: 25275265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
    Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The distribution of the major peripheral blood T, B and NK cell subsets does not predict the clinical outcome of Graves' disease patients after methimazole therapy.
    Corrales JJ; López A; Ciudad J; Orfao A
    J Biol Regul Homeost Agents; 2000; 14(3):193-9. PubMed ID: 11037052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
    Schott M; Morgenthaler NG; Fritzen R; Feldkamp J; Willenberg HS; Scherbaum WA; Seissler J
    Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of thyroxine upon prevention of recurrence of Graves' disease treated with antithyroid drugs].
    Wu G; Jie Y; Situ Y
    Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):274-5. PubMed ID: 11798886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study.
    Glaser NS; Styne DM;
    Pediatrics; 2008 Mar; 121(3):e481-8. PubMed ID: 18267979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
    Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
    Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse following antithyroid drug therapy for Graves' hyperthyroidism.
    Laurberg P; Krejbjerg A; Andersen SL
    Curr Opin Endocrinol Diabetes Obes; 2014 Oct; 21(5):415-21. PubMed ID: 25111942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
    Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission.
    Eckstein AK; Lax H; Lösch C; Glowacka D; Plicht M; Mann K; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):607-12. PubMed ID: 17880407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graves' disease in childhood: advances in management with antithyroid drug therapy.
    Kaguelidou F; Carel JC; Léger J
    Horm Res; 2009; 71(6):310-7. PubMed ID: 19506387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.